JCO oncology practice · 2026
Feasibility Study: Early Experiences With a Cancer Center's Virtual Expert Medical Opinion Program.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lipitz-Snyderman Allison, Chimonas Susan, Raftery Brendan, Levine Lauren Klein, Manship Cole, Giralt Sergio, Traina Tiffany, Sugarman Steven, Roman Benjamin R
Аннотация
PURPOSE: Second opinion consultations are a promising strategy to identify errors in diagnosis and recommend optimal treatment. Yet, there are geographic barriers. By bringing high-level care to patients where they live, virtual second opinion programs might benefit populations without access to specialty cancer centers. We conducted a feasibility study that examined changes in treatment recommended through a national virtual second opinion program based at a comprehensive cancer center.
METHODS: Memorial Sloan Kettering Cancer Center (MSK)'s virtual second opinion program was developed via a national cancer employer benefits solution. Each review was conducted by an MSK subspecialist and supported by a digital platform. After conducting the second opinion, subspecialists answered a questionnaire regarding their perceptions of the expected impact of recommended treatment changes. Here, we report findings from December 2023 to November 2024.
RESULTS: There were 231 cases completed. There were 55% women, with a median age of 56 years. Patients resided across the United States, with 56% from the South. The most common cancer categories were breast, GI and mixed tumor (GMT), and prostate. Cases were reviewed by 76 unique subspecialists. Subspecialists perceived that they made a meaningful change in recommended treatment (expected to affect patient outcomes) in 75 cases (32%). Expected changes included better prognosis/survival (n = 49, 65%), improved short-term morbidity/quality of life/toxicity (n = 36, 48%), or improved long-term morbidity/quality of life/toxicity (n = 49, 65%). There was a higher percent of recommended changes for liquid compared with solid tumor cases (liquid: 15 of 31, 48%; solid: 60 of 200, 30%).
CONCLUSION: Findings are helpful for understanding the potential impact of a virtual second opinion program for patients with cancer and for developing strategies to reach underserved communities with geographic access barriers to high-quality cancer care from subspecialists.
METHODS: Memorial Sloan Kettering Cancer Center (MSK)'s virtual second opinion program was developed via a national cancer employer benefits solution. Each review was conducted by an MSK subspecialist and supported by a digital platform. After conducting the second opinion, subspecialists answered a questionnaire regarding their perceptions of the expected impact of recommended treatment changes. Here, we report findings from December 2023 to November 2024.
RESULTS: There were 231 cases completed. There were 55% women, with a median age of 56 years. Patients resided across the United States, with 56% from the South. The most common cancer categories were breast, GI and mixed tumor (GMT), and prostate. Cases were reviewed by 76 unique subspecialists. Subspecialists perceived that they made a meaningful change in recommended treatment (expected to affect patient outcomes) in 75 cases (32%). Expected changes included better prognosis/survival (n = 49, 65%), improved short-term morbidity/quality of life/toxicity (n = 36, 48%), or improved long-term morbidity/quality of life/toxicity (n = 49, 65%). There was a higher percent of recommended changes for liquid compared with solid tumor cases (liquid: 15 of 31, 48%; solid: 60 of 200, 30%).
CONCLUSION: Findings are helpful for understanding the potential impact of a virtual second opinion program for patients with cancer and for developing strategies to reach underserved communities with geographic access barriers to high-quality cancer care from subspecialists.